Monitoring of a heart hormone (NT-proBNP) in the dialysis population for the prediction of major cardiovascular events

Not Applicable

Recruiting

• Conditions: Dialysis; Cardiomyopathy; Heart Failure; Sudden Cardiac Death; Kidney Disease; Renal and Urogenital - Kidney disease; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12612000836831
• Lead Sponsor: Centre for Kidney Disease Research, Princess Alexandra Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

In-centre haemo- or peritoneal dialysis patients established on dialysis for at least 90-days
Established on a single dialysis modality for at least 30-days
Aged 18-years or older
Temporary or permanent vascular access
Able to provide informed consent

Exclusion Criteria

Advanced malignancy and/or current malignancy undergoing evaluation and/or treatment – excludes skin cancers
Permanent pacemaker and/or implantable cardiac defibrillator
Limb amputee
Living donor renal transplant planned within 3-months of enrolment
Home haemodialysis
Congenital heart disease (excluding haemodynamically insignificant patent foramen ovale)
Acute renal impairment with the expectation of spontaneous recovery of renal function
Pregnancy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fatal and Non-fatal coronary vascular events[Monthly for 24-months];Fatal and Non-fatal heart failure[Monthly for 24-months];Fatal and non-fatal Arrhythmic events[Monthly for 24-months]

Secondary Outcome Measures

Name	Time	Method
Fatal and non-fatal peripheral vascular events[Monthly for 24-months];Death due to any cause[Monthly for 24-months];Hospitalisation for any cause[Monthly for 24-months];Deterioration in echocardiographic indices of left ventricular systolic and diastolic function[1-year and 2-years];Deterioration in pulse wave analysis and pulse wave velocity[1-year and 2-years]